Naobios

HIV cell
#Biotechnology #Clinical trials #HIV #Immunology / Virology & Vaccines #Naobios #Sumagen

Naobios and Sumagen partner to develop HIV vaccine 

Naobios has signed a partnership agreement with Sumagen, a Korean-Canadian biotechnology company developing an HIV-1 vaccine candidate, to manage the manufacturing process during its Phase II clinical trials.  At the end of 2022, the World Health Organization (WHO) reported that approximately 39 million people were living with HIV. Developing an… Read More

#Business & Investment #News

Vaccine development
#Bill & Melinda Gates Foundation #Funding #Immunology / Virology & Vaccines #Naobios #Omicron

Naobios receives $1.87 million in support of vaccine development 

Naobios, a CDMO providing bioprocess development and GMP production of clinical batches of virus-based products, has received a $1.87 million grant from the Bill & Melinda Gates Foundation in support of vaccine development.   Naobios will manufacture a human viral challenge agent that will be used to evaluate… Read More

#News